Opdualag (nivolumab and relatlimab)

pCPA File Number: 22581
Negotiation Status:
Under consideration for negotiation
Opdualag (nivolumab and relatlimab) is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma who have not received prior systemic therapy for unresectable or metastatic melanoma
Bristol Myers Squibb
CADTH Project Number:
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable